Artivion, Inc. (NYSE:AORT) Stock Holdings Lifted by Wellington Management Group LLP

Wellington Management Group LLP raised its position in Artivion, Inc. (NYSE:AORT) by 5.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,396,731 shares of the company’s stock after purchasing an additional 121,476 shares during the quarter. Wellington Management Group LLP owned approximately 0.06% of Artivion worth $31,397,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Money Concepts Capital Corp bought a new stake in shares of Artivion during the 4th quarter worth about $28,000. Quadrant Capital Group LLC bought a new stake in shares of Artivion during the 4th quarter worth about $31,000. Captrust Financial Advisors bought a new stake in shares of Artivion during the 2nd quarter worth about $39,000. State of Wyoming boosted its stake in shares of Artivion by 207.1% during the 4th quarter. State of Wyoming now owns 3,495 shares of the company’s stock worth $42,000 after acquiring an additional 2,357 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its stake in shares of Artivion by 54.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 3,859 shares of the company’s stock worth $47,000 after acquiring an additional 1,353 shares in the last quarter. Hedge funds and other institutional investors own 83.32% of the company’s stock.

Artivion Price Performance

NYSE AORT opened at $15.72 on Friday. Artivion, Inc. has a twelve month low of $9.64 and a twelve month high of $22.45. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.30 and a current ratio of 4.69. The stock has a market capitalization of $645.15 million, a PE ratio of -22.46 and a beta of 1.39. The stock has a 50-day simple moving average of $16.55 and a 200 day simple moving average of $14.89.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.05. The business had revenue of $89.25 million during the quarter, compared to analysts’ expectations of $84.45 million. Artivion had a positive return on equity of 1.97% and a negative net margin of 8.66%. Research analysts anticipate that Artivion, Inc. will post 0.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reiterated a “buy” rating and set a $26.00 price target on shares of Artivion in a research note on Friday, August 4th.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.